| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 464.71 | 1.8% | 0.1% |
| Total Income | 485.51 | 1.6% | 0.5% |
| Expenditure | 428.33 | 6.0% | 0.8% |
| PBT | 36.38 | 4.5% | 28.9% |
| Net Profit | 28.30 | 0.2% | 23.6% |
| OPM | 6.78% | 0.37pp | 2.89pp |
| NPM | 5.83% | 0.08pp | 1.84pp |
| EPS | 1.74 | 0.6% | 23.7% |
FDC Limited Announces Q3 FY26 Results: Revenue Growth of 0.1%, EBITDA Margin at 11.2%
05 Feb 2026 · 5 Feb, 6:16 pm
Summary
FDC Limited has announced its financial results for the third quarter and nine months ended December 31, 2025. The company's revenue from operations stood at Rs. 465 crores, registering a marginal growth of 0.1% Y-o-Y. The EBITDA for Q3 FY26 stood at Rs. 52 crores, with margins at 11.2%. The Domestic Formulations business showed a de-growth of 5.2% Y-o-Y, while the Export Formulations business grew by 55.0% Y-o-Y.
Key Highlights
- 1
Revenue from operations for Q3 FY26 is Rs. 465 crores with a growth of 0.1% Y-o-Y
- 2
EBITDA for Q3 FY26 is Rs. 52 crores with a margin of 11.2%
- 3
Domestic Formulations business showed a de-growth of 5.2% Y-o-Y
- 4
Export Formulations business grew by 55.0% Y-o-Y
- 5
API business registered sales of Rs. 23 crores in Q3 FY26, down by 17.0% Y-o-Y
- 6
FDC received U.S. FDA approval for Pilocarpine Ophthalmic Solution 1%, 2% and 4%
- 7
FDC markets more than 300 products in India and exports many of these to over 50 countries
Management Comments
Name of the person (if mentioned)
Comment of the person (if mentioned)
Informational and educational content only. Not investment advice.